Kaitlan Collins @kaitlancollins
Kramer told Congress he thinks Emergent will resume production of Johnson & Johnson as early as this week. They're waiting on FDA authorization. He also said they already have the material for what would amount to about 100 million doses, pending FDA evaluation. — PolitiTweet.org
